title: Lipoteichoic acid promotes nuclear accumulation of β-catenin via AKT in human gingival fibroblasts.
abstract: Treatment of human gingival fibroblasts (HGFs) with lipoteichoic acid (LTA) results in the activation of multiple signaling pathways. Exposure of HGF to LTA has been shown to result in the activation of phosphatidylinositol 3-kinase (PI3K). The aim of this study was to evaluate the effects of LTA-induced PI3K activation in HGFs. We found that LTA treatment results in the phosphorylation of AKT and glycogen synthase kinase (GSK-3). Inactivation of GSK-3 promotes the nuclear accumulation of β-catenin and expression of connexin43. Treatment with PI3K inhibitors, wortmannin and LY294002, inhibited LTA-induced phosphorylation of AKT and GSK-3, demonstrating that these events require PI3K activation. This report is the first demonstration that LTA treatment activates AKT in HGFs.
authors.affiliation: Laboratorio de Bioquímica, División de Estudios de Posgrado e Investigación, Facultad de Odontología, Universidad Nacional Autónoma de México, Ciudad de México, Mexico. gloria@fo.odonto.unam.mx
authors.forename: Gloria
authors.initials: G
authors.lastname: Gutiérrez-Venegas
authors.forename: Patricia
authors.initials: P
authors.lastname: Cardoso-Jiménez
mesh_terms: D000730:Androstadienes / Q000494:pharmacology; D002462:Cell Membrane / Q000187:drug effects / Q000378:metabolism; D002467:Cell Nucleus / Q000187:drug effects / Q000378:metabolism; D002478:Cells, Cultured; D002867:Chromones / Q000494:pharmacology; D018031:Connexin 43 / Q000378:metabolism; D005347:Fibroblasts / Q000187:drug effects* / Q000378:metabolism; D005881:Gingiva / Q000166:cytology / Q000187:drug effects* / Q000378:metabolism; D038362:Glycogen Synthase Kinase 3 / Q000037:antagonists & inhibitors / Q000378:metabolism; D006801:Humans; D008070:Lipopolysaccharides / Q000494:pharmacology*; D009025:Morpholines / Q000494:pharmacology; D019869:Phosphatidylinositol 3-Kinases / Q000378:metabolism; D010766:Phosphorylation / Q000187:drug effects; D017346:Protein Serine-Threonine Kinases / Q000378:metabolism; D021381:Protein Transport / Q000187:drug effects; D051057:Proto-Oncogene Proteins c-akt / Q000037:antagonists & inhibitors / Q000378:metabolism*; D000081382:Pyruvate Dehydrogenase Acetyl-Transferring Kinase; D015398:Signal Transduction / Q000187:drug effects; D013682:Teichoic Acids / Q000494:pharmacology*; D000077191:Wortmannin; D051176:beta Catenin / Q000378:metabolism*
chemical_list: D000730:Androstadienes; D002867:Chromones; D018031:Connexin 43; D038362:Glycogen Synthase Kinase 3; D008070:Lipopolysaccharides; D009025:Morpholines; D019869:Phosphatidylinositol 3-Kinases; D017346:Protein Serine-Threonine Kinases; D051057:Proto-Oncogene Proteins c-akt; D000081382:Pyruvate Dehydrogenase Acetyl-Transferring Kinase; D013682:Teichoic Acids; D000077191:Wortmannin; D051176:beta Catenin; C085911:2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one; C009900:lipoteichoic acid